This study looks at a new medicine called **olomorasib** to treat a type of lung cancer called KRAS G12C-mutant **non-small cell lung cancer (NSCLC)**. The study aims to see if olomorasib, when combined with standard medicines like **pembrolizumab** or **durvalumab**, works better than standard medicines alone. Participants might take part for up to **3 years**.

To join the study, you must have a confirmed diagnosis of NSCLC and a specific change in the cancer gene called **KRAS G12C mutation**. You should also be able to take pills and have good lab test results. Women must have a negative pregnancy test and not breastfeed during the study.

People can't join if they have other types of cancer needing treatment, certain gene changes, or severe reactions to similar medicines before. Those with active autoimmune diseases that needed treatment in the last 2 years also can't join.

• Study may last up to 3 years.
• Participants need to take pills.
• Women must have a negative pregnancy test and not breastfeed.